OSHA fines UCB for plant violations; Dr. Reddy's positioned for big expired-patent benefit;

 @FiercePharma: GSK, Merck tops at delivering meds to the poor. Report | Follow @FiercePharma

> Worker exposure to methylene chloride, a potential cause of cancer, has landed UCB Manufacturing in hot water with the Occupational Safety and Health Administration. And the drugmaker's Rochester, NY, plant may be in for more than $350,000 in fines. Report

> Dr. Reddy's Laboratories may be the biggest beneficiary among Indian generics makers as $157 billion of medicines--including Eli Lilly's Zyprexa--lose patent protection within five years, HDFC Securities said. Report

> The FDA will soon start posting online information about the year's food, drug and medical device recalls. Report

> Consolidated Pharmaceutical agreed to pay $250,000 in fines, never again own a business in Maryland and sell its long-dormant Baltimore-area penicillin-making site as part of a plea to criminal charges stemming from its abandonment of toxic chemicals there. Report

> Forest Laboratories and Merz Pharmaceuticals won the FDA nod for their extended-release dementia drug Namenda XR. Release

> APP Pharmaceuticals received FDA approval for its generic version of the Bristol-Myers Squibb anti-infective treatment Aztreonam. Report

Biotech News

 @FierceBiotech: FDA experts unanimously reject Boehringer's female libido pill. Article | Follow @FierceBiotech

 @JohnCFierce:  Amylin laid off 60 staffers, including research workers. Wants to look 'outside' more. Article | Follow @JohnCFierce

> HHS report underscores big shift to foreign drug trials. Story

> Pain startup lands $43M round, option to sell for up to $228M. Item

> Ortho-McNeil inks twin diabetes pacts totaling $1B. Article

> Regulus pairs with Sanofi in $750M microRNA pact. Report

Biotech Research News

> UK plans £600 million biomedical facility. Report

> Pew names slate of outstanding young researchers. Article

> Novartis' MS blockbuster highlights potential of nature's drugs. News

> Gene therapy strategy cures Type 1 diabetes in mice. Article

> Cellceutix reports preclinical progress on cancer therapy. Story

Manufacturing News

> J&J's stock dips in wake of recall. Report

> Ryder gets patent for supply chain method. Story

> GS1, India develop tracking system for recalls. Article

> Big pharma sees opportunity in Russia. News

And Finally... A "rewritten" flu virus prompts an identical immune response in mice to a natural infection, meaning it could make a more effective vaccine than traditional options. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.